Moderna, Inc. (NASDAQ:MRNA) Shares Sold by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 91.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,650 shares of the company’s stock after selling 37,949 shares during the period. John G Ullman & Associates Inc.’s holdings in Moderna were worth $363,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MRNA. First Pacific Financial acquired a new position in Moderna during the 3rd quarter worth $27,000. ICA Group Wealth Management LLC acquired a new position in Moderna during the 4th quarter worth $27,000. Arlington Trust Co LLC grew its holdings in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares in the last quarter. Stonebridge Capital Advisors LLC grew its holdings in Moderna by 79.1% during the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after acquiring an additional 125 shares in the last quarter. Finally, Ancora Advisors LLC grew its holdings in Moderna by 41.2% during the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after acquiring an additional 96 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the completion of the sale, the director now directly owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the completion of the sale, the insider now directly owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The disclosure for this sale can be found here. Insiders sold 109,954 shares of company stock valued at $11,533,976 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of recent research reports. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. HSBC reissued a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Canaccord Genuity Group raised their target price on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a research note on Tuesday, January 2nd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $125.00 target price on shares of Moderna in a research note on Thursday, March 28th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus price target of $126.49.

Moderna Stock Down 0.6 %

MRNA stock opened at $101.41 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $144.43. The firm has a 50 day moving average of $100.63 and a two-hundred day moving average of $93.64.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.61 earnings per share. On average, sell-side analysts predict that Moderna, Inc. will post -7.51 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.